Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including: For additional information on these and other important public announcements, visit the news section of Lilly's website. Financial Results A discussion of the non-GAAP financial measures is included under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Third-Quarter Reported Results In Q3 2022, worldwide revenue was $6.94 billion, an increase of 2% compared with Q3 2021, driven by a 14% increase in volume, partially offset by a 7% decrease due to lower realized prices and a 4% decrease from the unfavorable impact of foreign exchange rates. Key growth products, consisting of Verzenio ®, Trulicity ®, Mounjaro, Jardiance ®, Taltz ®, Emgality ®, Retevmo, Cyramza ®, Tyvyt ® and Olumiant ®, grew 19% and represented 70% of revenue for Q3 2022, excluding revenue from COVID-19 antibodies.